Evolution and progress of lung transplantation: An analysis of a cohort of 600 lung transplant patients at the Hospital Foch

• Published in: Revue des maladies respiratoires Vol. 36; no. 2; p. 142
• Main Authors: Roux, A, Sage, E, Cerf, C, Le Guen, M, Picard, C, Hamid, A M, Parquin, F, Stern, M, Bonnette, P
• Format: Journal Article
• Language: French
• Published: France 01.02.2019
• Subjects: Ex-vivo; Graft survival; Transplantation pulmonaire; CLAD; Survie du greffon; Lung transplantation; Dysfonction chronique du greffon; Emergency lung transplantation; Transplantation pulmonaire en super-urgence
• ISSN: 1776-2588
• DOI: 10.1016/j.rmr.2018.02.014

Lung transplantation is deemed to be the only effective therapy that improves survival for patients with end stage lung disease. The aim of our study was to examine the progress achieved over the last two decades and to demonstrate the effectiveness and safety of this treatment. A retrospective analysis of a cohort of 600 consecutive lung transplant patients treated at the hospital Foch (Suresnes, France) between 1988 and 2014. They were split into three groups of 200 patients each: 1988-2004, 2004-2011, 2011-2014. Time and mortality on waiting list, perioperative mortality, the incidence of acute rejection in the first year and chronic lung allograft dysfunction (CLAD) at 5 years posttransplantation, have all decreased. Global survival at 1 and 5 years for the 600 patients increased from 78% and 57% to 86% and 75% respectively for the 200 last patients. Patients with cystic fibrosis have a better 5 year survival than those with emphysema or pulmonary fibrosis (68% vs. 54 % for emphysema and 37% for fibrosis). For the last 200 patients, 5 year survival is 81% for CF patients, 78 % for emphysema and 47% for fibrosis. Emergency transplantation had a 60% 5 years survival. Proliferative complications, arterial hypertension and renal function impairment are being monitored long term. The twenty-five years experience shows a consistent improvement in the results of lung transplantation which is now accepted as the only effective curative treatment for end stage lung disease.